SecBot SecBot
8-K ·Filed Sep 9, 2026

PYXS

Pyxis Oncology, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed2mo ago SEC0001193125-26-385901
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

For traders, this data de-risks MICVO's monotherapy profile and sets a clear catalyst path: combo data (Q4 2026), End of Phase 2 meeting (Q1 2027), updated overall survival (1H 2027), and Phase 3 initiation (mid-2027). Monitor for any safety signals as the trial expands (peripheral neuropathy Gr3 in 17.1% of patients).

DirectionBullish
Confidencehigh
Horizonmonths

PYX-201

◆ Mixed Named in this 8-K
Impact
Phase
Phase 1 / Phase 1/2
Time to market
At least 2-3 years, assuming Phase 3 trial (planned mid-2027) succeeds and leads to an NDA filing. No regulatory filing has occurred yet.
Next catalyst
None dated

What to watchThe next near-term catalyst is the EORTC-NCI-AACR late-breaking oral presentation (Nov 18-20, 2026), though the top-line data has already been disclosed. The true binary events are: Q4 2026 updated combo data, Q1 2027 End-of-Phase 2 meeting with FDA, and H1 2027 overall survival data from the monotherapy study, any of which could drive major moves. The $3.50 common warrant exercise trigger (requiring both shareholder approval and OS data) creates an additional overhang that could cap upside until clarity emerges.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$3.38
T+0 close · Sep 9, 2026 · via day close
Latest settled
−40.53%
T+20 · $2.01 · next T+60 in 16d
Vs SPY
−42.48%
α at T+20
Latest observation
−44.33%
T+46 · FF3 residual α
  1. T+0 · Sep 9 $3.38entry
  2. T+1 · 2mo ago −3.25%α −2.65% · $3.27
  3. T+5 · 2mo ago −1.18%α −0.09% · $3.34
  4. T+20 · 6w ago −40.53%α −42.48% · $2.01
  5. T+48 · todayOpen
  6. T+60 · in 16d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pyxis Oncology announced positive updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). The data show a 36% confirmed objective response rate, 94% disease control rate, median progression-free survival of 6.2 months, and a 12-month overall survival probability of 79%, substantially exceeding historical control benchmarks. Safety was manageable with dose capping, supporting advancement into a pivotal Phase 3 trial (Headliner) planned for mid-2027.

Key Facts

  • 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR) in 2L+ R/M HNSCC (N=33 efficacy evaluable)
  • Median progression-free survival (mPFS) of 6.2 months; 12-month overall survival probability of 79% (median OS not yet reached)
  • Clinical activity observed across HPV status and prior-treatment subgroups, including prior EGFRi-exposed patients
  • No new safety signals; dose capping reduced frequency and severity of adverse events, especially peripheral neuropathy
  • Phase 3 Headliner trial planned for mid-2027; End of Phase 2 meeting with FDA expected Q1 2027
  • Updated data from MICVO + KEYTRUDA (pembrolizumab) combination in 1L R/M HNSCC expected Q4 2026

Financial Impact

No financial data in filing; positive clinical data supports potential for a multi-billion-dollar addressable market (>$4B US TAM in 2L+ HNSCC per company estimates) but revenue still zero as company is pre-commercial

Risk Factors

  • Early stage: Phase 1 data, small sample size (N=33 efficacy evaluable), and cross-trial comparisons are not head-to-head
  • Safety: Grade 3 peripheral neuropathy in 17.1% and 14% discontinuation rate; need to monitor in larger Phase 3
  • Competitive landscape: novel EGFRi therapies (e.g., petosemtamab) may shift 1L treatment and affect 2L+ trial enrollment
  • Regulatory risk: Phase 3 design requires alignment with FDA on dose selection (Project Optimus) and co-primary endpoints (ORR and OS)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-385901
Document: pyxs-ex99_1.htm0001193125-26-385901
Document: pyxs-ex99_2.htm0001193125-26-385901
Document: 0001193125-26-385901-index-headers.html0001193125-26-385901
Document: 0001193125-26-385901-index.html0001193125-26-385901
Document: 0001193125-26-385901.txt0001193125-26-385901

Track record

25 reports on PYXS

Performance horizon

6 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
  3. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
  5. Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
  6. Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
  7. Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
  8. Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
  9. Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
  10. Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 31m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026